Suivre les négociations dans les Amériques, étudier les formes nouvelles que prend
l’intégration, servir de carrefour de recherche et participer au débat public.


Marc-André Gagnon

Hill Times op-ed by Dr. Marc-Andre Gagnon : The $2-billion extra price tag of brand-name drugs in Canada

7 février 2011

Canadians often think that their prescription drugs are cheap. Otherwise, why would so many Americans cross the border to buy them ?

Yet in the last five years, Canada has been the world’s third most expensive country for brand-name drugs.

In 1987, Canada passed changes to the Patent Act extending patent protection for prescription drugs from 17 to 20 years after brand-name drug companies agreed to spend 10 per cent of their sales on research and development. The rationale was simple : a generous patent policy for brand-name companies would ensure a more competitive, innovative pharmaceutical sector in Canada.

(Pour lire la suite, cliquez ici)